1 Min Read
July 10 (Reuters) - Vistagen Therapeutics Inc:
* Vistagen Therapeutics appoints Dr. Mark Wallace to clinical advisory board to advance AV-101 as a potential non-opioid treatment for neuropathic pain Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.